ProShare Advisors LLC Sells 649 Shares of Genomic Health, Inc. (GHDX)
ProShare Advisors LLC cut its holdings in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 3.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 19,371 shares of the medical research company’s stock after selling 649 shares during the quarter. ProShare Advisors LLC owned about 0.06% of Genomic Health worth $631,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Dubuque Bank & Trust Co. grew its stake in Genomic Health by 8.4% during the 2nd quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock valued at $159,000 after acquiring an additional 379 shares in the last quarter. SG Americas Securities LLC raised its holdings in Genomic Health by 37.8% in the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock valued at $199,000 after acquiring an additional 1,679 shares during the last quarter. Legal & General Group Plc raised its holdings in Genomic Health by 48.7% in the 1st quarter. Legal & General Group Plc now owns 6,222 shares of the medical research company’s stock valued at $196,000 after acquiring an additional 2,038 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Genomic Health in the 1st quarter valued at about $218,000. Finally, Envestnet Asset Management Inc. raised its holdings in Genomic Health by 13.6% in the 1st quarter. Envestnet Asset Management Inc. now owns 8,282 shares of the medical research company’s stock valued at $259,000 after acquiring an additional 993 shares during the last quarter. Hedge funds and other institutional investors own 88.90% of the company’s stock.
Genomic Health, Inc. (NASDAQ GHDX) opened at 31.71 on Wednesday. The firm’s market capitalization is $1.10 billion. Genomic Health, Inc. has a 12-month low of $26.37 and a 12-month high of $33.97. The firm has a 50-day moving average of $31.11 and a 200 day moving average of $31.60.
Genomic Health (NASDAQ:GHDX) last released its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.02). Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The company had revenue of $85.50 million during the quarter, compared to analyst estimates of $86.08 million. During the same period last year, the firm earned ($0.18) earnings per share. The business’s revenue was up 4.3% compared to the same quarter last year. On average, equities analysts predict that Genomic Health, Inc. will post ($0.02) EPS for the current year.
In related news, insider James J. Vaughn sold 8,000 shares of the business’s stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $30.59, for a total value of $244,720.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Kimberly J. Popovits sold 5,000 shares of the company’s stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $31.00, for a total transaction of $155,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 36,174 shares of company stock worth $1,132,171. Corporate insiders own 46.20% of the company’s stock.
GHDX has been the topic of a number of research reports. Jefferies Group LLC reissued a “hold” rating and issued a $33.00 target price on shares of Genomic Health in a research note on Monday, June 12th. Zacks Investment Research lowered Genomic Health from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st. Cowen and Company restated a “hold” rating and issued a $34.00 price target on shares of Genomic Health in a research report on Friday, September 1st. Canaccord Genuity reaffirmed a “buy” rating and issued a $35.00 price target on shares of Genomic Health in a report on Wednesday, September 27th. Finally, BidaskClub cut Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $32.00.
Genomic Health Company Profile
Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.
Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).
Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.